Cargando…

Iranian Pulmonary Arterial Hypertension Registry

BACKGROUND: Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disorder with a prevalence of 8.6 per million. We introduce a registry website for IPAH and PAH patients ( www.IPAH.ir) for access and efficient delivery of government-aided and subsidized antihypertensive medications. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Masjedi, Mohammad Reza, Fahimi, Fanak, Sharif-Kashani, Babak, Malek Mohammad, Majid, Saliminejad, Leila, Monjazebi, Fateme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Research Institute of Tuberculosis and Lung Disease 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629425/
https://www.ncbi.nlm.nih.gov/pubmed/26528365
_version_ 1782398573690748928
author Masjedi, Mohammad Reza
Fahimi, Fanak
Sharif-Kashani, Babak
Malek Mohammad, Majid
Saliminejad, Leila
Monjazebi, Fateme
author_facet Masjedi, Mohammad Reza
Fahimi, Fanak
Sharif-Kashani, Babak
Malek Mohammad, Majid
Saliminejad, Leila
Monjazebi, Fateme
author_sort Masjedi, Mohammad Reza
collection PubMed
description BACKGROUND: Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disorder with a prevalence of 8.6 per million. We introduce a registry website for IPAH and PAH patients ( www.IPAH.ir) for access and efficient delivery of government-aided and subsidized antihypertensive medications. MATERIALS AND METHODS: The IPAH registry was opened in November 2009. Information of IPAH and PAH patients with a username and password were uploaded in the site. Data entry was possible only via the physicians and healthcare organizations via internet that were given a personalized username and password for entry. Following the patients’ profile submission, a scientific committee composed of a cardiologist and a pulmonologist who were selected by the Ministry of Health of Iran (MOH), evaluated the data. The eligibility of the patient to receive the medications was confirmed after evaluation. If the patient was eligible, 82% of the Bosentan cost was paid by MOH. RESULTS: To date, one hundred and sixteen patients (82 females, 34 males) have been registered. The mean pulmonary artery pressure by right heart catheterization was 69.24±17 mmHg (ranging from 35 to 110 mmHg). CONCLUSION: The first online Iranian registry program for IPAH and PAH patients is believed to supply essential information for health care providers in the field.
format Online
Article
Text
id pubmed-4629425
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher National Research Institute of Tuberculosis and Lung Disease
record_format MEDLINE/PubMed
spelling pubmed-46294252015-11-02 Iranian Pulmonary Arterial Hypertension Registry Masjedi, Mohammad Reza Fahimi, Fanak Sharif-Kashani, Babak Malek Mohammad, Majid Saliminejad, Leila Monjazebi, Fateme Tanaffos Original Article BACKGROUND: Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disorder with a prevalence of 8.6 per million. We introduce a registry website for IPAH and PAH patients ( www.IPAH.ir) for access and efficient delivery of government-aided and subsidized antihypertensive medications. MATERIALS AND METHODS: The IPAH registry was opened in November 2009. Information of IPAH and PAH patients with a username and password were uploaded in the site. Data entry was possible only via the physicians and healthcare organizations via internet that were given a personalized username and password for entry. Following the patients’ profile submission, a scientific committee composed of a cardiologist and a pulmonologist who were selected by the Ministry of Health of Iran (MOH), evaluated the data. The eligibility of the patient to receive the medications was confirmed after evaluation. If the patient was eligible, 82% of the Bosentan cost was paid by MOH. RESULTS: To date, one hundred and sixteen patients (82 females, 34 males) have been registered. The mean pulmonary artery pressure by right heart catheterization was 69.24±17 mmHg (ranging from 35 to 110 mmHg). CONCLUSION: The first online Iranian registry program for IPAH and PAH patients is believed to supply essential information for health care providers in the field. National Research Institute of Tuberculosis and Lung Disease 2015 /pmc/articles/PMC4629425/ /pubmed/26528365 Text en Copyright© 2015 National Research Institute of Tuberculosis and Lung Disease This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Masjedi, Mohammad Reza
Fahimi, Fanak
Sharif-Kashani, Babak
Malek Mohammad, Majid
Saliminejad, Leila
Monjazebi, Fateme
Iranian Pulmonary Arterial Hypertension Registry
title Iranian Pulmonary Arterial Hypertension Registry
title_full Iranian Pulmonary Arterial Hypertension Registry
title_fullStr Iranian Pulmonary Arterial Hypertension Registry
title_full_unstemmed Iranian Pulmonary Arterial Hypertension Registry
title_short Iranian Pulmonary Arterial Hypertension Registry
title_sort iranian pulmonary arterial hypertension registry
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629425/
https://www.ncbi.nlm.nih.gov/pubmed/26528365
work_keys_str_mv AT masjedimohammadreza iranianpulmonaryarterialhypertensionregistry
AT fahimifanak iranianpulmonaryarterialhypertensionregistry
AT sharifkashanibabak iranianpulmonaryarterialhypertensionregistry
AT malekmohammadmajid iranianpulmonaryarterialhypertensionregistry
AT saliminejadleila iranianpulmonaryarterialhypertensionregistry
AT monjazebifateme iranianpulmonaryarterialhypertensionregistry